The Effective Statistician - in association with PSI

Part 2 I'm reviewing the first page of the awesome Novartis cheat sheet on data visualization. Click here to get your download of the sheet! Given that this is especially helpful in a visual way, I have recorded this as a video. Have fun watching and please forward it to your colleagues. https://www.youtube.com/watch?v=bQMCMAfBva8

Part 1 I'm reviewing the first page of the awesome Novartis cheat sheet on data visualization. Click here to get your download of the sheet! Given that this is especially helpful in a visual way, I have recorded this as a video. Have fun watching and please forward it to your colleagues.

Interview with Björn Bornkamp and Kaspar Rufibach In this episode, I talk with 2 experts from Novartis and Roche. We cover the following questions: What is Principal Stratification?How would you describe principal stratification to a non-statistician?Where do you see the benefits of this estimand compared to the other typical strategies?Which critique points do are usually raised against this approach?How do you implement/calculate corresponding estimates for this estimand?What references would you recommend for further reading? Björn and Kaspar recommend the following very useful references: References: Books:Introduction into potential outcomes and causal inference: https://www.cambridge.org/core/books/causal-inference-for-statistics-social-and-biomedical-sciences/71126BE90C58F1A431FE9B2DD07938ABHernan and Robins: https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/ Pearl, the book of why: https://www.amazon.de/Book-Why-Science-Cause-Effect/dp/046509760XPapers:Paper draft: https://arxiv.org/abs/2008.05406 with markdown: https://oncoestimand.github.io/princ_strat_drug_dev/princ_strat_example.html and github: https://github.com/oncoestimand/princ_strat_drug_devMagnusson et al (Siponimod Beispiel): https://onlinelibrary.wiley.com/doi/full/10.1002/sim.8333 and the corresponding EPAR: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdfOncology estimand working group: http://www.oncoestimand.org/ 

Interview with Yves Schymura As part of his master thesis, he worked on an idea; I had sketched out a couple of years ago but never had the time to fully think through. I wanted to explore how we could utilize existing study data to inform the benefit-risk assessment of different therapies. In this episode, you will learn a new concept which also is related to minimal clinical meaningful differences and helps to assess the impact of various adverse events on the patient. Specifically, we dive into: What is the benefit-risk tolerability measure?How can we use the information on which patient discontinue to inform the benefit-risk assessment?How does the model help us rank adverse events in order of their importance?Which adverse events cannot be classified with the model?How to use the model to inform relevant difference for efficacy endpoints? Listen to this episode and share it with your friends and colleagues!

Interview with Nicholas Lowthorpe Join us in today's episode as we are talking about the following points: LyricAnswerQuestion"Cherry lips, crystal skiesI could show you incredible things."Taylor talks of her mastery of colour, as she alludes to the incredible insights she can display through just a splash of red against a crystal-clear background.What are your key learnings regarding colour?"Find out what you wantBe that girl for a month."Unlike many data projects, Taylor's will succeed - because she takes the time to find out what her stakeholders want, and agrees clear deadlines.How does your practice look like to learn about the needs of the stakeholders?"So it's gonna be forever or it's gonna go down in flames."Unlike many data projects, Taylor's will succeed - because she takes the time to find out what her stakeholders want, and agrees clear deadlines.How does your practice look like to learn about the needs of the stakeholders?"But I've got a blank space, babyAnd I'll write your name."Taylor's only mistake. My advice would be to leave that space blank and clutter free.How do you measure the success of your visualization? Reference blog: https://www.linkedin.com/feed/update/urn:li:activity:6709808936557580289/ Listen to this episode now and share this with your friends and colleagues!

Interview with Victoria Gamerman In this episode, Victoria and I talk about the following points: What is design thinking?Why is it important?What are the different aspects of design thinking?What are the examples for application of design thinking within data science and statistics? Reference: Design Thinking Comes of Age

Very tricky situation! In this episode, I will show you through this example how you can get what you need and have the other person feel good about it. Does this sound like manipulation? No, this is finding a common way that helps everybody.  Listen to this episode now and share this with your friends and colleagues!

Interview with Stephen Bungay In this episode, you will take a lot of learnings for your everyday life. Specifically, we also discuss the following: How did the Romans and French organize their military?What can we learn from the military's way?How to give support and boundaries the right way?How to take action?How to achieve good results? Listen to this episode to learn more and share this with your friends and colleagues.

In today's episode, I am sharing about my experience I had earlier in my career when I was working on a lot of different publications with different physicians who were responsible with these studies. Listen to this episode and share this with your friends and colleagues who can learn from it!

Book review with Stuart McGuire You will see from our discussion the AHA moments Stuart had by reading this book and the important points I've learned. Here are a few, we dive in more deeply: How to be good in negotiationSeparate the people from the problemFocus on interests, not positionsWork together to create opinions that will satisfy both partiesNegotiate successfully with people who are more powerful, refuse to play by the rules, and/or resort to “dirty tricks” Listen to this episode now and share it with your friends and colleagues!